Respiratory syncytial virus (RSV) season is unpredictable
Make sure your practice is prepared
Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection is available through VaccineShop,* VaxServe, and select wholesalers and distributors.† Simply create an account or log in to your existing account to order Beyfortus with immediate shipping.
*All direct customers on VaccineShop will receive a 2% discount and 90-day billing terms. Excludes wholesale, distributor, and public orders.
†Beyfortus 50 mg and 100 mg Injection is available to purchase through wholesalers and distributors. Please call 1-800-VACCINE for more information.
A single dose for the vast majority of infants based on body weight (5O mg intramuscular [IM] dose if <5 kg, 100 mg IM dose if ≥5 kg)3
For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose is recommended as soon as the child is stable after surgery. Please consult the Prescribing Information for complete information on dosing in this circumstance. Second season: children up to 24 months of age, regardless of body weight, who remain at increased risk for severe RSV, the recommended dosage of Beyfortus is a single 200 mg dose administered as 2 IM injections (2 x 100 mg).
Each Beyfortus pre-filled syringe is for one-time use only.3
How Beyfortus is supplied3
Beyfortus is a sterile, preservative-free injection solution that appears clear to opalescent and colorless to yellow.
Packaging and delivery type
Pre-filled syringe
Beyfortus is an IM injection administered through a pre-filled syringe by a healthcare provider.
1-pack and 5-pack cartons
Each carton of Beyfortus contains 1 or 5 pre-filled syringes.
Dose strengths and formulation
First RSV season
<5 kg weight 50 mg/0.5 mL
NDC: 49281 - 575 - 15
First RSV season
≥5 kg weight 100 mg/1 mL
NDC: 49281-574-15
Second RSV season
Any weight 2 x 100 mg/1 mL
NDC: 49281-574-15
Product images are representative of scale—actual size of packaging may be different.
Important Safety Information
References: 1. Arriola CS, Kim L, Langley G, et al. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9(5):587-595. 2. RSV in infants and young children. Centers for Disease Control and Prevention. August 30, 2024. Accessed July 22, 2025. https://www.cdc.gov/rsv/infants-young-children/index.html 3. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi.
